title: [Study of the durability of the triple antiretroviral regimens].
abstract: OBJECTIVE
  The evaluation of the effectiveness of triple antiretroviral therapies (TTT) in HIV-infected patients is difficult due to the long duration of these therapies. Our objective was to estimate the treatment's duration until the failure of the triple antiretroviral combination as a subrogated variable of the effectiveness.
  
  
  METHODS
  Survival time calculation of a triple antiretroviral combination in 356 adult HIV-infected patients (from 1997 to 2001) and study of the influence of both the triple combination type (TC) and the presence or absence of previous antiretroviral treatment (TP).
  
  
  RESULTS
  The survival median time was 21.96 months. There were not statistical differences related to TC (n1 = 241, n2 = 108, p = 0.4916) but to TP (n3 = 106, n4 = 250, p = 0.0460).
  
  
  CONCLUSIONS
  The time in which TTT turned out to be effective seems to be short. It could explain the variety of TTT employed in clinical practice.
authors.affiliation: Servicio de Farmacia, Hospital Universitario de Getafe, Ctra. de Toledo, km. 12,500, 28905 Getafe, Madrid, Spain.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Martínez Sesmero
authors.forename: Javier
authors.initials: J
authors.lastname: Sánchez-Rubio Ferrández
authors.forename: Ana
authors.initials: A
authors.lastname: Ontañón Nasarre
authors.forename: Nuria
authors.initials: N
authors.lastname: Ibáñez Heras
authors.forename: Cristóbal
authors.initials: C
authors.lastname: Montojo Guillén
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D019380:Anti-HIV Agents